Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039. J Natl Cancer Inst Monogr. 2010. PMID: 20956824 Free PMC article. Review.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Lancet. 2011 Nov 12;378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Lancet. 2011. PMID: 22019144 Free PMC article. Review.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28. Lancet. 2011. PMID: 21802721 Free PMC article.
[Discussion. Meeting on the diagnosis and treatment of lung cancer].
Hirata K, Takayama K, Kawaguchi T, Sawa K, Ohsaki Y. Hirata K, et al. Among authors: sawa k. Nihon Naika Gakkai Zasshi. 2014 Jun 10;103(6):1360-74; quiz 1375-81. doi: 10.2169/naika.103.1360. Nihon Naika Gakkai Zasshi. 2014. PMID: 25151802 Japanese. No abstract available.
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Mitsuoka S, Kawaguchi T, Kubo A, Isa S, Asai K, Uji M, Watanabe T, Sawa K, Yoshimoto N, Oka T, Nakai T, Suzumura T, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Kudoh S, Hirata K. Mitsuoka S, et al. Among authors: sawa k. Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18. Expert Opin Pharmacother. 2016. PMID: 26781399 Review.
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.
Matsumoto Y, Kawaguchi T, Yamamoto N, Sawa K, Yoshimoto N, Suzumura T, Watanabe T, Mitsuoka S, Asai K, Kimura T, Yoshimura N, Kuwae Y, Hirata K. Matsumoto Y, et al. Among authors: sawa k. Intern Med. 2017 Sep 1;56(17):2325-2328. doi: 10.2169/internalmedicine.8467-16. Epub 2017 Aug 10. Intern Med. 2017. PMID: 28794368 Free PMC article.
Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report.
Yoshimura N, Tada T, Matsumoto Y, Sawa K, Yoshimoto N, Suzumura T, Tanaka H, Mitsuoka S, Kimura T, Tamiya T, Hirashima T, Kawaguchi T, Kudoh S, Hosono M, Hirata K. Yoshimura N, et al. Among authors: sawa k. Am J Clin Oncol. 2018 Oct;41(10):967-971. doi: 10.1097/COC.0000000000000412. Am J Clin Oncol. 2018. PMID: 29045265 Clinical Trial.
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Sawa K, Koh Y, Kawaguchi T, Kambayashi S, Asai K, Mitsuoka S, Kimura T, Yoshimura N, Yoshimoto N, Kubo A, Saka H, Matsumura A, Wanibuchi H, Yamamoto N, Nishiyama N, Hirata K. Sawa K, et al. Lung Cancer. 2017 Oct;112:96-101. doi: 10.1016/j.lungcan.2017.07.039. Epub 2017 Aug 7. Lung Cancer. 2017. PMID: 29191607
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Izumi M, Ogawa K, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Koh Y, Kawaguchi T. Matsumoto Y, et al. Among authors: sawa k. Cancer Sci. 2019 Oct;110(10):3244-3254. doi: 10.1111/cas.14156. Epub 2019 Aug 30. Cancer Sci. 2019. PMID: 31368625 Free PMC article.
121 results